At a glance
ClinicalIndex Comparison RecordN/ACompleted· 53 enrolled
Drug / intervention
Treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis
In Brief
An observational study evaluating Treatment for Axial Spondyloarthritis. Completed, enrolled 53 participants across 6 sites.
Detailed Summary
The study investigates different criteria for remission based on MRI and circulating biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates factors that affect disease activity, function and participation by use of different questionnaires.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis
CountriesDenmark
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedDec 2013
Primary CompletionFeb 2017
TodayJul 2026
First PostedDec 13, 2013
Enrollment StartFeb 1, 2013
Primary CompletionFeb 14, 2017
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 12.6 years ago
Interventions
Treatmentdrug